Mesoblast (ASX:MSB) reported a financial milestone, announcing that net sales for its flagship product, Ryoncil (remestemcel-L-rknd), reached US$30.3 million for the quarter ended March 31.
The performance marks a pivotal moment for the global leader in allogeneic cellular medicines, as total revenue generated during the first year of the product’s launch now approaches the US$100 million mark.
The March quarter results were bolstered by strong growth throughout February and March, which effectively offset the anticipated holiday seasonality observed in January.
Company leadership noted that the steady revenue stream is materially strengthening Mesoblast’s balance sheet, providing the necessary capital to support label extensions and advance late-stage "blockbuster" clinical programmes.
Ryoncil holds a unique position in the market as the first mesenchymal stromal cell product approved by the US Food and Drug Administration for any indication.
It currently remains the only FDA-approved therapy for children under age 12 suffering from steroid-refractory acute graft-versus-host disease (SR-aGvHD).